All In Biotech

Drug Trial Radar · NCT01388504

Nitrites in Acute Myocardial Infarction

Does Sodium Nitrite Administration Reduce Ischaemia-reperfusion Injury in Patients Presenting With Acute ST Segment Elevation Myocardial Infarction?

Last checked: Nov 19, 2026Latest source record: Jan 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Jul 2011

Primary completion

Jan 2014

Study completion Jan 2014

Sponsor

Lead sponsor
University of AberdeenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NHS Grampian; Medical Research Council; St George's Healthcare NHS Trust; Brighton and Sussex University Hospitals NHS Trust; Imperial College London; University of Birmingham
First posted
Jul 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research question to be addressed is "Does a 2.5 - 5 minute systemic intravenous injection of sodium nitrite administered immediately before opening of the infarct related artery result in significant reduction of ischaemia reperfusion injury in patients with first acute ST elevation myocardial infarction (MI)?"

Conditions

  • Acute ST Elevation Myocardial Infarction

Interventions

  • sodium nitriteDrug

    sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention

  • PlaceboOther

    sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infarct size corrected for area at risk (using ESA)Time frame: 6-8 days post injection

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom

  • Brighton and Sussex University Hospitals NHS Trust

    Brighton, United Kingdom

  • St George's Healthcare NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.